Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$114.17 USD

114.17
188,391

+0.22 (0.19%)

Updated Oct 7, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy

by Zacks Equity Research

Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.

    Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction

    by Zacks Equity Research

    Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.

      Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara

      by Zacks Equity Research

      Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.

        Novartis (NVS) Reports Positive Data on Biosimilar Humira

        by Zacks Equity Research

        Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.

          Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss

          by Zacks Equity Research

          Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.

            Medicines Company (MDCO) Q4 Loss Narrower than Expected

            by Zacks Equity Research

            The Medicines (MDCO) reported a loss of $1.29 per share (including the impact of share-based compensation expenses) in the fourth quarter of 2016, narrower than Zacks Consensus Estimate of a loss of $1.43.

              Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?

              by Zacks Equity Research

              Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.

                Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates

                by Zacks Equity Research

                Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.

                  Arpita Dutt headshot

                  Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

                  by Arpita Dutt

                  Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

                    Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

                    by Zacks Equity Research

                    Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

                      Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

                      by Zacks Equity Research

                      Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

                        Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

                        by Zacks Equity Research

                        Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

                          Model N (MODN) Q1 Loss Narrower than Expected, Guides Well

                          by Zacks Equity Research

                          Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.

                            Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

                            by Zacks Equity Research

                            Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

                              Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

                              by Zacks Equity Research

                              Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

                                Novartis (NVS) Votubia Gets EU Approval for Label Expansion

                                by Zacks Equity Research

                                Novartis (NVS) wins EU approval for label expansion of Votubia in refractory partial-onset seizures in patients with tuberous sclerosis complex.

                                  GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

                                  by Zacks Equity Research

                                  GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

                                    Momenta Says District of Delaware Invalidates Teva's MS Drug

                                    by Zacks Equity Research

                                    Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

                                      Arpita Dutt headshot

                                      Drug Stocks Rally on Trump Meet with Pharma Bigwigs

                                      by Arpita Dutt

                                      Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.

                                        Madeleine Johnson headshot

                                        Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

                                        by Madeleine Johnson

                                        Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

                                          Ryan McQueeney headshot

                                          Biotech Stocks Gain on Latest Trump Drug Price Statements

                                          by Ryan McQueeney

                                          President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

                                            Incyte and Calithera Enter into Deal for Oncology Candidate

                                            by Zacks Equity Research

                                            Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

                                              Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

                                              by Zacks Equity Research

                                              Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                                                Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug

                                                by Zacks Equity Research

                                                Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).

                                                  Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon

                                                  by Zacks Equity Research

                                                  Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.